CXCR4-targeted PET/CT for hematologic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective imaging comparison in patients with newly diagnosed or relapsed hematological malignancies who will undergo both 68Ga‑pentixafor PET/CT and standard 18F‑FDG PET/CT. The scans will be compared for lesion detection, concordance, staging accuracy, and relation to established risk stratification systems. Longitudinal follow-up will link imaging findings to clinical outcomes and prognosis. The protocol also explores deep learning–based image segmentation and other AI techniques to enhance image analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Volunteer to participate and sign an informed consent form;
2. 18 ≤ Age ≤ 90 years;
3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;
4. Willing and able to follow schedule visits, treatment plans and laboratory tests.

Exclusion Criteria:

1. pregnancy or breastfeeding;
2. Allergic to CXCR4-targeted tracers or excipients;
3. Fasting blood glucose level exceeded 11.0 mmol/L prior to injection of 18F-FDG;
4. Those who cannot complete PET/CT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;
5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.

Where it's running

• Zhongnan Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yong He, MD, PhD — Zhongnan Hospital
• Study coordinator: Yong He, MD, PhD
• Email: vincentheyong@163.com
• Phone: +86-27-67812698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Omni 128 cm PET/CT imaging system: comparing new scanner with standard PET/CT

  This study tests a new Omni 128 cm PET/CT scanner by having adults with a planned clinical PET/CT also undergo an extra research scan to compare image quality.

  Recruiting GE Healthcare · Stanford, California · NCT07857161

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

• DLL3-targeted PET/CT for small cell lung cancer

  This study tests whether DLL3-targeted PET/CT can better detect lesions in people with suspected or confirmed small cell lung cancer compared with standard imaging.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07677787

• FAP-targeted PET and near-infrared fluorescence imaging for resectable non-small cell lung cancer

  We are testing whether FAP-targeted PET and near-infrared fluorescence can help find residual tumor and guide surgery in people with stage II–IIIB resectable non-small cell lung cancer after neoadjuvant therapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07498933

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.